Simon Krabbe
Biologic Agents(Simon Krabbe)은 Rheumatoid Arthritis 표적 치료제로, Rheumatoid Arthritis; Spondyloarthritis 영역에서 개발·상용화 중입니다. 작용기전: targeting specific inflammatory pathway. 전임상 단계입니다. 대표 임상 효능: ORR 22% (ClinicalTrials.gov NCT00894803). 차별점: unique value of avian-derived scFv in recognizing conserved epitopes and overcoming immune tolerance, along with engineering s.
Rheumatoid Arthritis
Rheumatoid Arthritis; Spondyloarthritis
Active
gene therapy approaches are evaluated within a translational framework
humanized Fc domains and half-life extension technologies, offer a promising and customizable strategy for ne
unique value of avian-derived scFv in recognizing conserved epitopes and overcoming immune tolerance, along with engineering s
targeting specific inflammatory pathway
immune-mediated reactions, including sarcoidosis-like reactions due to immune dysregulation
apoptosis and cell growth, including PARP, Caspase-3, Bcl-2, AKT, and mTOR
biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu
resistance to FKBP12-dependent immunosuppressive agents, including tacrolimus, everolimus, and sirolimus, with TRAC knockout to elimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Simon Krabbe
Biologic Agents(Simon Krabbe)은 Rheumatoid Arthritis 표적 치료제로, Rheumatoid Arthritis; Spondyloarthritis 영역에서 개발·상용화 중입니다. 작용기전: targeting specific inflammatory pathway. 전임상 단계입니다. 대표 임상 효능: ORR 22% (ClinicalTrials.gov NCT00894803). 차별점: unique value of avian-derived scFv in recognizing conserved epitopes and overcoming immune tolerance, along with engineering s.
Rheumatoid Arthritis
Rheumatoid Arthritis; Spondyloarthritis
Active
gene therapy approaches are evaluated within a translational framework
humanized Fc domains and half-life extension technologies, offer a promising and customizable strategy for ne
unique value of avian-derived scFv in recognizing conserved epitopes and overcoming immune tolerance, along with engineering s
targeting specific inflammatory pathway
immune-mediated reactions, including sarcoidosis-like reactions due to immune dysregulation
apoptosis and cell growth, including PARP, Caspase-3, Bcl-2, AKT, and mTOR
biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu
resistance to FKBP12-dependent immunosuppressive agents, including tacrolimus, everolimus, and sirolimus, with TRAC knockout to elimi
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.